Preclinical Neuroscience CRO

Start with what you're working on

Search for the model or assay you have in mind, or go straight to a therapeutic area or platform.

By model or assay

Search our catalog of preclinical disease models and assays by name or indication.

Browse all models and assays

By therapeutic area

Disease areas, each with its indications and services.

By platform

The technologies and study types behind each area.

See which platforms support each area

Evidence across species, before the clinic

Decades of experience in cross-species and cross-therapeutic-area translational biology help carry programs from early rodent studies through to large animal species, so the decision to go into the clinic rests on more than one species.

Rodent: Rodent models Gold standard and transgenic rodent models across therapeutic areas. Disease Models & Mechanisms, 2024: Impact of distinct dystrophin gene mutations on behavioral phenotypes of Duchenne muscular dystrophy (opens in new tab)
Humanized mouse: Humanized models Humanized-liver PXB mouse studies for human metabolite prediction and drug-drug interaction assessment. Newsletter, August 2025: New Capabilities Coming Online
PK-Bridge: PK-Bridge Translational PK bridging from rodent to large animal species, including beagle dogs. Pharmaceutical Research, 2022: Pharmacokinetics and pharmacodynamic effect of a blood-brain barrier-crossing fusion protein therapeutic for Alzheimer's disease in rat and dog (opens in new tab)
Aged beagle: Naturally occurring disease Our aged beagle colony for naturally developing age-related disease, including Alzheimer's-like cognitive decline and osteoarthritic pain. Pharmacology Research & Perspectives, 2020: Treatment of Porphyromonas gulae infection and downstream pathology in the aged dog by lysine-gingipain inhibitor COR388 (opens in new tab)

For more than 25 years, our scientists have helped drug developers answer one critical question: will this therapy succeed in patients?

CNS drug development can stall when disease models fail to reflect human biology, biomarkers and endpoints do not translate across species, or target engagement and efficacy remain unclear. Addressing these challenges early can help reveal translational gaps before significant time and investment are committed to clinical development.

We put science and our clients first, working collaboratively to challenge assumptions, solve problems and find better ways forward. By combining specialized neuroscience expertise, clinically relevant disease models, translational biomarkers, advanced behavioral science and cross-species biology, we generate the evidence needed to strengthen go/no-go decisions and build greater confidence in the path to the clinic.

We work with biotech, pharmaceutical and animal health innovators worldwide, bringing integrity, scientific rigor and ownership to every program, helping clients reduce development risk and move promising therapies toward the clinic with greater confidence. As always, science remains our passion.

Read our publications